Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism

@article{Araki2004InhibitionOT,
  title={Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism},
  author={Kazunori Araki and Norio Yasui-Furukori and Takashi Fukasawa and Toshiaki Aoshima and Akihito Suzuki and Yasunori Inoue and Tomonori Tateishi and Koichi Otani},
  journal={European Journal of Clinical Pharmacology},
  year={2004},
  volume={60},
  pages={427-430}
}
ObjectiveTo clarify the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of etizolam.MethodsThe effects of itraconazole, a potent and specific inhibitor of CYP3A4, on the single oral dose pharmacokinetics and pharmacodynamics of etizolam were examined. Twelve healthy male volunteers received itraconazole (200 mg/day) or placebo for 7 days in a double-blind randomized crossover manner, and on the 6th day they received a single oral 1-mg dose of etizolam. Blood samplings and evaluation… Expand
Induction of the metabolism of etizolam by carbamazepine in humans
TLDR
The present study suggests that carbamazepine induces the metabolism of etizolam, and significantly decreased the peak plasma concentration and total area under the plasma concentration–time curve. Expand
Notable Drug–Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19
TLDR
It is found that in vitro measurements of fraction metabolized (fm) using the liver microsome prepared from PM donors would be helpful to predict polymorphism‐dependent DDIs. Expand
Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity
TLDR
The present study suggests that the single-dose pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. Expand
Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism.
TLDR
Erythromycin treatment significantly increased the peak plasma concentration, total area under the plasma concentration-time curve, and elimination half-life of brotizolam and provides in vivo evidence for the involvement of CYP3A4 in brotIZolam metabolism. Expand
Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs.
TLDR
The results suggest that the psychotropic drugs investigated are metabolized predominantly by CYP3A4, except that CYP2D6 catalyzes the metabolism of imipramine, which is useful for the identification of the responsible CYP isoform(s) of older drugs. Expand
Rifampicin Markedly Decreases Plasma Concentration and Hypnotic Effect of Brotizolam
TLDR
It is suggested that rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam and, therefore, this combination is not recommended in clinical practice. Expand
Bioanalytical methods for the determination of itraconazole and hydroxyitraconazole: overview from clinical pharmacology, pharmacokinetic, pharmacodynamic and metabolism perspectives.
TLDR
This review focuses on providing comprehensive details on the bioanalytical methods available for the quantitation of both itraconazole and hydroxyitraconazer, and provides an overview of the clinical pharmacology, pharmacokinetics, pharmacodynamics and metabolism related aspects of itraconsazole. Expand
Pharmacokinetic interactions between Japanese traditional Kampo medicine and modern medicine (IV). Effect of Kamisyoyosan and Tokisyakuyakusan on the pharmacokinetics of etizolam in rats.
TLDR
In in vitro experiment, KSS and TSS inhibited CYP3A activity comparable to grapefruit juice, however in in vivo experiments, oral administration of KSS did not influence the plasma concentration profile of etizolam, and in vitro inhibitory effect of KRS or TSS on rat cytochrome P450 (CYP) 3A activity in rat microsomes was unsuccessful. Expand
Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: Prediction of in vivo drug interactions
TLDR
The present study predicted the possibility of drug interactions between mexiletine and paroxetine, fluoxetines, desipramine, and thioridazine in clinical use by using the in vitro Ki and unbound inhibitor concentrations in liver. Expand
27 Antifungal drugs
TLDR
It is found that compared with conventional amphotericin B deoxycholate, lipid-based formulations are less nephrotoxic and that terbinafine is well tolerated in this population over short periods of time. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 27 REFERENCES
Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam
TLDR
It is suggested that itraconazole, a potent CYP3A4 inhibitor, increases plasma concentration of alprazolam via its inhibitory effects on alpazolam metabolism, which supports previous studies suggesting that CYP 3A4 is the major enzyme catalyzing the metabolism of al prazol am. Expand
No Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Estazolam
TLDR
The current study showed no significant effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam, suggesting that cytochrome P450 3A4 is not involved in the metabolism of estazerolam to a major extent. Expand
Effects of Itraconazole on the Plasma Kinetics of Quazepam and Its Two Active Metabolites after a Single Oral Dose of the Drug
TLDR
The present study suggests that CYP 3A4 is partly involved in the metabolism of quazepam, and itraconazole treatment did not affect either of the psychomotor function parameters. Expand
Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam
TLDR
The present study suggests that carbamazepine decreases plasma concentration of alprazolam by inducing its metabolism, and supports the previous studies, suggesting that alpazolam is metabolized predominantly by CYP3A4. Expand
Effects of Genetically Determined S–Mephenytoin 4–Hydroxylation Status and Cigarette Smoking on the Single–Dose Pharmacokinetics of Oral Alprazolam
TLDR
It is suggested that neither S–mephenytoin 4–hydroxylation status nor self–reports reports of extensive cigarette smoking has a major impact on the metabolism of alprazolam in humans. Expand
Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype
TLDR
The metabolism of both diazepam and demethyldiazepam is related to the mephenytoin, but not to the debrisoquin, hydroxylation phenotype, and there was no significant difference in volume of distribution of the benzodiazepines between the phenotypes. Expand
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
Interaction between ketoconazole, itraconazole, and midazolam was investigated in a double‐blind, randomized crossover study of three phases at intervals of 4 weeks. Nine volunteers were given eitherExpand
Effects of the Antifungal Agents on Oxidative Drug Metabolism
TLDR
The interactions of ketoconazole with cyclosporin and tacrolimus have been applied for therapeutic purposes to allow a lower dosage and cost of the immunosuppressant and a reduced risk of fungal infections. Expand
Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam.
TLDR
The interactions of erythromycin with diazepam and flunitrazepam seem to be slight and of limited clinical significance only. Expand
Clinical Pharmacokinetics of Alprazolam
TLDR
Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 μg/L, which may be needed for suppression of the actual panic attacks. Expand
...
1
2
3
...